Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 5:13:949003.
doi: 10.3389/fendo.2022.949003. eCollection 2022.

A systematic review and meta-analysis of endocrine-related adverse events associated with interferon

Linghuan Wang  1   2 , Binqi Li  1   2 , He Zhao  1 , Peixin Wu  1 , Qingzhen Wu  1 , Kang Chen  2 , Yiming Mu  1   2
Affiliations
Meta-Analysis

A systematic review and meta-analysis of endocrine-related adverse events associated with interferon

Linghuan Wang et al. Front Endocrinol (Lausanne). .

Abstract

Objectives: To perform a systematic review and meta-analysis of interferon and endocrine side effects, including their incidence, evaluation, and management.

Methods: PubMed was searched through March 7th, 2021, by 2 authors independently (LH Wang and H Zhao). Early phase I/II, phase III experimental trials, prospective and retrospective observational studies were included. Stata 16.0 (StataCorp LLC, 16.0) was the main statistical software for meta-analysis. The weighted incidence and risk ratio were estimated for primary thyroid disease and diabetes mellitus.

Results: A total of 108 studies involving 46265 patients were included. Hypothyroidism was the most common thyroid disorder, followed by hyperthyroidism. IFN α+RBV treated patients experienced hypothyroidism in 7.8% (95%CI, 5.9-9.9), which was higher than IFN α (5.2%; 95%CI, 3.7-6.8) and IFN β (7.0%; 95%CI, 0.06-23.92). IFN α+RBV treated patients experienced hyperthyroidism in 5.0% (95%CI, 3.6-6.5), which was higher than IFN α (3.5%; 95%CI, 2.5-4.8) and IFN β (3.4%; 95%CI, 0.9-7.5). The summary estimated incidence of painless thyroiditis was 5.8% (95%CI, 2.8-9.8) for IFN α, and 3.5% (95%CI,1.9-5.5) for IFN α+RBV. The summary estimated incidence of diabetes was 1.4% (95%CI, 0.3-3.1) for IFN, 0.55% (95%CI, 0.05-1.57) for IFN α, 3.3% (95%CI,1.1-6.6) for IFN α+RBV.

Conclusions: Our meta-analysis shows a high incidence of endocrine adverse events provoked by IFN, further reinforced by combined RBV treatment.

Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022334131.

Keywords: endocrine adverse events; hyperthyroidism; hypothyroidism; interferon; thyroiditis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of study selection.
See this image and copyright information in PMC

References

    1. Russo M, Fried M. Side effects of therapy for chronic hepatitis c. Gastroenterology (2003) 124(6):1711–9. doi: 10.1016/S0016-5085(03)00394-9 - DOI - PubMed
    1. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol (1996) 24(1):38–47. doi: 10.1016/S0168-8278(96)80184-X - DOI - PubMed
    1. Tran HA, Malcolm Reeves GE, Gibson R, Attia JR. Development of thyroid diseases in the treatment of chronic hepatitis c with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis. J Gastroenterol Hepatol (2009) 24(7):1163–8. doi: 10.1111/j.1440-1746.2009.05874.x - DOI - PubMed
    1. Manns M, Wedemeyer H, Cornberg M. Treating viral hepatitis c: efficacy, side effects, and complications. Gut (2006) 55(9):1350–9. doi: 10.1136/gut.2005.076646 - DOI - PMC - PubMed
    1. de Filette J, Andreescu C, Cools F, Bravenboer B, Velkeniers B. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Hormone Metab Res (2019) 51(3):145–56. doi: 10.1055/a-0843-3366 - DOI - PubMed

Publication types